Mankind Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma has informed stock exchanges that the trading window for dealing in its shares will be closed from October 1, 2025, until 48 hours after the company declares its unaudited financial results for the quarter and half year ending September 30, 2025. During this period, designated employees, their immediate relatives, and connected persons are barred from trading in the company's stock. The closure is in line with SEBI's insider trading regulations and the company's internal code of conduct. The date of the board meeting to approve the Q2 and H1 FY26 results has not been announced yet and will be communicated later.
This is a routine compliance announcement ahead of the upcoming Q2 FY26 earnings release. It does not impact business operations or shareholders directly, but signals that the results announcement is likely in mid-to-late October 2025.